Lymphocytes in the treatment with interferon beta-1 b

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F17%3A10368291" target="_blank" >RIV/00216208:11150/17:10368291 - isvavai.cz</a>

Alternative codes found

RIV/00179906:_____/17:10368291

Result on the web

<a href="http://dx.doi.org/10.1016/j.msard.2017.08.020" target="_blank" >http://dx.doi.org/10.1016/j.msard.2017.08.020</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.msard.2017.08.020" target="_blank" >10.1016/j.msard.2017.08.020</a>

Result language

angličtina

Original language name

Lymphocytes in the treatment with interferon beta-1 b

Original language description

Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease affecting the central nervous system. One of the basic medications for the treatment of a clinically isolated syndrome (CIS) or relapsing-remitting MS is interferon beta (INF beta). Although the exact mechanism of its effects is unknown, the medication has an anti-inflammatory and immunomodulatory effect. The goal of this study was to determine the characters which are affected in patients treated with INF beta. Methods: A total of 97 patients (25 males and 72 females) were included into the study. Patients were treated by INF beta 1-b (subcutaneous injection, 250 mu g, each other day). Clinical evaluations were performed by an attending neurologist. Peripheral blood samples were obtained just prior to treatment and 5 years after INF beta 1-b. Statistical analysis and processing of the obtained data were performed by using a comprehensive statistical software package MATLAB (R). Results: A significant decrease of the observed parameters after 5 years&apos; of treatment (significant at the 1% significance level) was found in the absolute and relative CD69 count, absolute cytotoxic/suppressor T lymphocyte count, absolute total leukocyte count, absolute natural killer cells count. A significant decrease of the observed parameters after 5 years&apos; of treatment (significant at the 5% significance level) was found in the absolute lymphocyte count, relative cytotoxic/suppressor T lymphocyte count, relative CD3+CD69+ count and absolute CD8+CD38+ count. Conclusion: The treatment with interferon beta reduces clinical exacerbations in multiple sclerosis (MS) through several known immunomodulatory mechanisms. However, the exact mechanism of effect of this medication is not known. This study presents some parameters that were affected by the long-term INF beta treatment.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30103 - Neurosciences (including psychophysiology)

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Multiple Sclerosis and Related Disorders

ISSN

2211-0348

e-ISSN

—

Volume of the periodical

18

Issue of the periodical within the volume

neuvedeno

Country of publishing house

US - UNITED STATES

Number of pages

4

Pages from-to

29-32

UT code for WoS article

000415341300007

EID of the result in the Scopus database

2-s2.0-85029529107